Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ1UOI)

• Drug Name: ASP-015K Drug Info
• Synonyms: Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 3	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 57928403
  CAS Number: CAS 944118-01-8
  TTD Drug ID: DMZ1UOI
  INTEDE Drug ID: DR1774

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[6]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[7]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[8]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[7]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[9]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[10]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[11]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[12]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[7]
GDC-0214	DMCNSII	Asthma	CA23	Phase 1	[13]

Drug(s) Targeting Tyrosine-protein kinase (PTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[14]
Abrocitinib	DM8J29L	Atopic dermatitis	EA80	Approved	[7]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[15]
KD019	DMEFW3G	Brain metastases	2D50	Phase 2	[15]
LEO 124249	DM7W0JE	Asthma	CA23	Phase 2	[7]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-1473	DMJG7AY	Ulcerative colitis	DD71	Phase 1	[2]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[16]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[16]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[16]

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[8]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[17]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[18]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[19]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[7]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[2]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[3]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[7]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[9]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[10]

Drug(s) Metabolized By Sulfotransferase 2A1 (SULT2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[20]
Abiraterone acetate	DMANBZI	Prostate cancer	2C82.0	Approved	[21]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[22]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[23]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[20]
BCP-13498	DM2BO9W	N. A.	N. A.	Phase 2	[24]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[20]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[20]
Tetramethylbutylphenol	DMW9CH2	N. A.	N. A.	Investigative	[20]
N-nonylphenol	DMH3OUX	N. A.	N. A.	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[3]
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[4]
Tyrosine-protein kinase (PTK)	TTJSQEF	NOUNIPROTAC	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Sulfotransferase 2A1 (SULT2A1)	DE0P6LK	ST2A1_HUMAN	Substrate	[5]
Nicotinamide N-methyltransferase (NNMT)	DECVGJ3	NNMT_HUMAN	Substrate	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8315).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [5] Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [9] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [10] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [12] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [13] Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.
• [14] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [17] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [19] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
• [20] Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
• [21] Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
• [22] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
• [23] Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
• [24] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.